Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Market Movers
TipRanks 50 Index
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Private Companies
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans & Pricing
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Advertisement
Advertisement
CRVO
Stock Latest News
Company Announcements
CervoMed’s Neflamapimod Added to U.K. ALS Platform
1d ago
8K
CRVO
Premium
Ratings
CervoMed: Capital-Efficient Expansion of Neflamapimod Into ALS Platform Trial Supports Buy Rating and $20 Target
1d ago
CRVO
Premium
The Fly
CervoMed’s neflamapimod elected for inclusion in UK EXPERTS-ALS platform
2d ago
CRVO
Premium
Company Announcements
CervoMed Releases Updated Investor Presentation and Business Overview
1M ago
8K
CRVO
Premium
The Fly
CervoMed initiated with an Overweight at Cantor Fitzgerald
2M ago
CRVO
Premium
Ratings
CervoMed Initiated With Buy Rating on Differentiated DLB Asset Neflamapimod and De-Risked Path to 2029 Launch
2M ago
CRVO
Premium
Company Announcements
CervoMed’s Promising Phase 2b Trial Results for DLB
3M ago
8K
CRVO
Premium
The Fly
CervoMed’s neflamapimod shows efficacy in slowing dementia
3M ago
CRVO
Premium
Ratings
Optimistic Buy Rating for CervoMed Following Promising Phase 2b Trial Results and Strategic Insights
3M ago
CRVO
Premium
The Fly
CervoMed presents new data from Phase 2b RewinD-LB trial on neflamapimod
3M ago
CRVO
Premium
Ratings
CervoMed’s Promising First-Mover Advantage in Dementia with Lewy Bodies Treatment: Buy Rating Reaffirmed
3M ago
CRVO
Premium
Company Announcements
CervoMed Reports Q3 2025 Financial Results and Progress
3M ago
CRVO
Premium
Ratings
CervoMed’s Strategic Advancements and Clinical Trial Developments Drive Buy Rating
3M ago
CRVO
Premium
The Fly
CervoMed price target lowered to $19 from $20 at Roth Capital
3M ago
CRVO
Premium
The Fly
CervoMed reports Q3 EPS (84c), consensus (56c)
3M ago
CRVO
Premium
Ratings
CervoMed’s Promising Phase 3 Trial and Strategic Financial Position Support Buy Rating
3M ago
CRVO
Premium
The Fly
CervoMed upgraded to Buy from Neutral at H.C. Wainwright
4M ago
CRVO
Premium
Ratings
CervoMed’s Strategic Phase 3 Trial Progress for Neflamapimod Boosts Buy Rating
4M ago
CRVO
Premium
The Fly
CervoMed announces FDA alignment on neflamapimod registration path
4M ago
CRVO
Premium
Company Announcements
CervoMed Gains FDA Alignment for Phase 3 Trial
4M ago
8K
CRVO
Premium
Company Announcements
CervoMed Appoints David Quigley to Board of Directors
4M ago
8K
CRVO
Premium
The Fly
CervoMed appoints Quigley to board of directors
4M ago
CRVO
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >
You need to enable JavaScript to run this app.
